SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The Revenue for the quarter ended  December 2024 of Rs. 61918.10 millions grew by 22.04 % from Rs. 50737.50 millions.Handsome Net Profit growth of 63.74% reported above the corresponding previous quarter figure of Rs. 11810.50 millions to Rs. 7213.10 millions.Operating profit for the quarter ended December 2024 rose to 17718.60 millions as compared to 14358.00 millions of corresponding quarter ended December 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 61918.10 50737.50 22.04 158175.90 146360.30 8.07 202751.70 208121.40 -2.58
Other Income 683.90 2284.80 -70.07 3657.60 5079.50 -27.99 5534.80 3292.90 68.08
PBIDT 17718.60 14358.00 23.41 40405.90 40409.60 -0.01 60533.70 67518.90 -10.35
Interest 2159.60 2149.20 0.48 6757.90 5664.90 19.29 7840.80 4721.80 66.06
PBDT 15559.00 11510.70 35.17 33648.00 32554.50 3.36 50502.70 33419.20 51.12
Depreciation 2909.70 3996.00 -27.18 9463.10 12075.80 -21.64 16006.20 16008.70 -0.02
PBT 12649.30 7514.70 68.33 24184.90 20478.70 18.10 34496.50 17410.50 98.14
TAX 838.80 301.60 178.12 1363.30 572.90 137.96 5914.70 503.30 1075.18
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 11810.50 7213.10 63.74 22821.60 19905.80 14.65 28581.80 16907.20 69.05
Equity 2399.30 2399.30 0.00 2399.30 2399.30 0.00 2399.30 2399.30 0.00
PBIDTM(%) 28.62 28.30 1.12 25.54 27.61 -7.48 29.86 32.44 -7.97

Sun Pharma Inds. Share Price

1847.30 12.90 (0.70%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×